7 July 2023
Vaccines Receives an Increased Impact Factor of 7.8 and an Improved Category Ranking
We are pleased to inform you that Vaccines’ 2022 Impact Factor is 7.8. Vaccines (ISSN: 2076-393X) now ranks in the top Q1 in the categories “Immunology” (32/161) and “Medicine, Research and Experimental” (24/136).
For more journal statistics, please visit https://www.mdpi.com/journal/vaccines/stats.
The Vaccines Editorial Office would like to thank all authors, reviewers, and editors who have contributed to the journal.
Message from the Vaccines Editor-in-Chief:
|
Prof. Dr. Ralph A. Tripp |
An impact factor (IF) is a tool used to compare journals within the same field, based on the average number of citations that an article receives. It is often used to gauge a journal's importance within its field, as well as the ability of its editors to attract high-quality papers. Many research teams use IF to increase the visibility and impact of their work. Recently, the journal Vaccines was awarded an IF score of 7.8 for 2022, which is considered to be quite good. This achievement is a testament to the hard work and dedication of the Editorial Board, managing editors, and publishing staff at Vaccines. Congratulations are in order for their great effort and excellent results. |
Message from the Vaccines Associate Editor-in-Chief:
|
Prof. Dr. François Meurens |
2023—another great year in the history of Vaccines, brightened by a major accomplishment! With a new impact factor of 7.8 we have reached the first league! Let us continue like this and thanks to our excellent team, all the authors, the readers, and all the supporters of Vaccines for this collective success! |
Congratulations from Section Editors-in-Chief and Editorial Board Members:
Dr. Eduardo Gomez-Casado
Section Editor-in-Chief (Section: “Vaccine Adjuvants”)
“Congratulations! Great news! Vaccines has grown in a spectacular way in the last few months. I hope it continues to grow in the coming months.”
Prof. Dr. Giampiero Girolomoni
Section Editor-in-Chief (Section: “Clinical Immunology”)
“Congratulations!! Very happy to hear this.”
Prof. Dr. Hans-Peter Hartung
Section Editor-in-Chief (Section: “Cellular/Molecular Immunology”)
“Excellent news!”
Prof. Dr. Nirbhay Kumar
Section Editor-in-Chief (Section: “Vaccines against (re)emerging and Tropical Infections Diseases”)
“Vaccines has shown consistent efforts towards quality review, rapid publication and it is always striving to maintain a high standard. Its latest recognition by assigning an impact factor of 7.8 is a testimony in itself and the IF is at par, if not higher than other similar journals. While the impact factor is one way to assess a journal's reputation, what is more important is that the journal Vaccines actively seeks and publishes highly relevant articles, after a thorough peer-review, which have broader appeal and readership. I am particularly delighted to be a team member and look forward to working to raise the standard even higher with highest transparency.”
Dr. Ralph Joseph DiClemente
Section Editor-in-Chief (Section: “Vaccines and Society”)
“Great news! Happy to hear it!”
Dr. Subbaya Subramanian
Section Editor-in-Chief (Section: “Cancer Vaccines and Immunotherapy”)
“I wanted to take a moment to express my sincere appreciation and congratulate our editorial team on the remarkable news regarding the increased impact factor. This is truly a testament to the hard work and dedication of our editors, Editorial Office staff, and esteemed authors who have consistently contributed high-impact articles.”
Prof. Dr. Angelos Hatzakis
Section Board Member
“Exciting news! I feel proud as a member of the group of people participating in this success.”
Dr. James Galloway
Section Board Member
“That is absolutely fantastic news!”
Dr. Kim D. Thompson
Editorial Board Member
“That is excellent news—it is down to the excellent management of the journal!”
Prof. Dr. Vasso Apostolopoulos
Section Board Member
“It is exciting to see the new impact factor for 2022 for Vaccines jump to 7.8 and be ranked Q1 in the categories “Immunology” and “Medicine, Research and Experimental”. Being an editor of the journal, I have noticed an increase in very high-quality vaccine research papers, especially in the last 3 years. Vaccines has now become the preferred journal to publish the latest groundbreaking research in the area.”
